Chengye Medical's Key Subsidiary Fukan Vitality Pharmaceutical Announces Board Resolution on Cash Capital Increase and New Share Issuance
AI Summary (NQ-processed)
Fukan Vitality Pharmaceutical Co., Ltd., a key subsidiary of Chengye Medical, has announced a board resolution on June 26, 2025, to issue new shares via a cash capital increase. The total issuance amount is NT$77,466,400, comprising 880,300 ordinary shares, with proceeds allocated to strengthen operational funding.
AI Analysis
Frequently Asked Questions
Q: How much is Fukan Vitality Pharmaceutical's capital increase?
A: NT$77,466,400 by issuing 880,300 new shares.
Q: What will the raised funds be used for?
A: Entirely for operational capital to enhance production and supply.
Q: Can employees purchase shares?
A: Yes, 88,030 shares are allocated for employee subscription.